Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Forest signs agreement with NPS Allelix for migraine therapy

Sep. 4, 2000

New indication for KW-6002 undergoes clinical testing

Sep. 4, 2000

THC derivative demonstrates safety, lack of marijuana-like effects in phase I trial

Sep. 1, 2000

Anxiolytic and antidepressant compounds with a dual mechanism of action

Aug. 31, 2000

New developments in neurological research at AstraZeneca

Aug. 31, 2000

NIDDK reports design of GPCR ligands

Aug. 31, 2000

Merck & Co. claims compounds useful for treating cognition disorders

Aug. 30, 2000

Neurogen discloses new series of compounds interacting with dopamine D4 receptors

Aug. 30, 2000

Lilly reports synthesis of novel mGlu2/3 agonists and antagonists

Aug. 30, 2000

AMPA/kainate receptor modulators claimed by Egis

Aug. 29, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...